- Datasheet
- Specific References
- Protocols
Overview
-
Product nameTSG101 peptide
Description
-
NatureSynthetic
Associated products
-
Corresponding Antibody
Specifications
Our Abpromise guarantee covers the use of ab30870 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Blocking - Blocking peptide for Anti-TSG101 antibody (ab30871)
-
FormLiquid
-
Additional notes
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
General Info
-
Alternative names
- ESCRT I complex subunit TSG101
- ESCRT-I complex subunit TSG101
- TS101_HUMAN
see all -
FunctionComponent of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses.
-
Tissue specificityHeart, brain, placenta, lung, liver, skeletal, kidney and pancreas.
-
Sequence similaritiesBelongs to the ubiquitin-conjugating enzyme family. UEV subfamily.
Contains 1 SB (steadiness box) domain.
Contains 1 UEV (ubiquitin E2 variant) domain. -
DomainThe UEV domain is required for the interaction of the complex with ubiquitin. It also mediates the interaction with PTAP/PSAP motifs of HIV-1 P6 protein and human spumaretrovirus Gag protein.
The coiled coil domain may interact with stathmin.
The UEV domain binds ubiquitin and P-[ST]-A-P peptide motif independently. -
Post-translational
modificationsMonoubiquitinated at multiple sites by LRSAM1 and by MGRN1. Ubiquitination inactivates it, possibly by regulating its shuttling between an active membrane-bound protein and an inactive soluble form. Ubiquitination by MGRN1 requires the presence of UBE2D1. -
Cellular localizationCytoplasm. Membrane. Nucleus. Late endosome membrane. Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Depending on the stage of the cell cycle, detected in the nucleus. Colocalized with CEP55 in the midbody during cytokinesis.
- Information by UniProt
References
ab30870 has not yet been referenced specifically in any publications.
Customer reviews and Q&As
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"